For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase ( ...

A study reveals that a personalized approach, considering age, sex and size, improves the diagnosis of hypertrophic ...

Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 ...

Women may be missing a diagnosis of a potentially deadly heart condition due to guidelines that don't account for natural differences in sex and body size.

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe ...

Women may be missing a diagnosis of a potentially deadly heart condition due to guidelines that don't account for natural differences in sex and body size, according to a new study led by UCL ...

Background and aims Hypertrophic cardiomyopathy (HCM) has various aetiologies, including genetic conditions like Fabry ...

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025. Edgewise Chief ...

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

Discover promising gene therapy results from Tenaya Therapeutics, Inc.'s TN-201 and TN-401 projects, potential impact on ...

Discover Trametinib as a promising treatment for severe hypertrophic cardiomyopathy in children with RASopathies.

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...